Michael J. Rosenberg

Michael Rosenberg focuses his practice on advising companies, investment banks, venture capital firms and strategic investors on a broad range of capital markets transactions, financings, M&A transactions as well as securities law filings and compliance, with a focus on the healthcare, life sciences, fintech, and technology industries.

Michael leverages extensive deal experience and his commercial approach to advising clients in offerings of equity and debt - publicly and privately. He represents domestic and international issuers in initial public offerings (IPOs), secondary offerings, confidentially marketed public offerings (CMPOs), 144A offerings, at-the-market (ATM) financings later-stage venture capital financings, private investments in public equity (PIPEs), registered direct offerings, and seed financings.

Honigman Law Israel is a wholly-owned Israeli subsidiary of Honigman LLP. Honigman Law Israel attorneys are qualified under and practice exclusively under U.S. law.

Practice Areas

Representative Matters

Capital Markets

• Advised the underwriters in connection with eToro’s US$712 million initial public offering.*
• Advised the underwriters in connection with Gauzy’s US$75 million initial public offering.*
• Advised Alpha Tau Medical, an Israel-based developer of the alpha-radiation cancer therapy Alpha DaRT™, in connection with its US$36.9 million registered direct offering.*
• Advised MediWound Ltd, an Israeli based biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio therapeutic, non-surgical solutions for tissue repair and regeneration, in its US$30 million registered offering and concurrent private placement.*
• Advised MediWound Ltd in its US$15 million registered offering.*
• Advised the underwriters in connection with a convertible bond offering by Camtek.*
• Advised SpringWorks Therapeutics in its US$186.3 million initial public offering and US$287.5 million follow-on offering.*
• Advised Scholar Rock Holding Corporation in its US$51 million and US$230 million public follow-on offerings.*
• Advised Research Alliance Corporation in its US$137 million initial public offering and concurrent private placement.*
• Advised Calliditas Therapeutics in its US$90 million initial public offering.*
• Advised Pliant Therapeutics in its US$165 million initial public offering.*
• Advised Kaleido Biosciences in its US$75 million initial public offering*
• Advised Advaxis in its US$20 million shelf offering.*
• Advised Allena Pharmaceuticals in its US$20 million registered direct offerings.*
• Advised Vascular Biogenics in its US$18 million registered direct offerings.*
• Advised the underwriters in connection with Immunome’s US$35 million initial public offering.*
• Advised the underwriters in connection with a follow-on offering for IntriCon Corporation.*
• Advised Zealand Pharma in its US$89 million initial public offering.*
• Advised Edge Therapeutics in its US$115 million initial public offering.*
• Advised Iconix Brand Group in its offering of High Yield Convertible Notes.*
• Advised Griffon Corporation in its 144A offerings of high yield debt securities.*
• Advised US Shale Solutions in its 144A offering of senior secured notes.*
• Advised the underwriters in connection with a follow-on offering for BioLineRx.*
• Advised Forward Pharma in its US$221 million initial public offering.*

Venture Capital

• Advised SpringWorks Therapeutics in its US$125 million Series B financing.*
• Advised Navitor Pharmaceuticals in its Series D and Series C financings and issuance of convertible notes.*
• Advised Imara Pharma in its US$63 million Series B financing.*

Mergers & Acquisitions

• Advised ironSource, a software company that focuses on app monetization and distribution, on its US$4.4 billion all stock merger with Unity Software.*
• Advised HUB Cyber Security on its US$1.28 billion business combination with Mount Rainier Acquisition Corp.*
• Advised Alpha Tau Medical, , on its US$1 billion business combination with Healthcare Capital Corp., a special purpose acquisition company.*
• Advised Itamar Medical, an Israeli based medical device and digital health company in its US$538 million sale to ZOLL Medical.*
• Advised ironSource on its US$11 billion business combination with Thoma Bravo Advantage, a special purpose acquisition company.*
• Advised Alpha Healthcare Acquisition Corp.’s business combination with Humacyte.*
• Advised Zealand Pharma’s US$205 million sale of certain royalty rights to Royalty Pharma.*
• Advised AM-Pharma’s sale of a minority interest in the company to Pfizer and related option payment.*
• Advised Dava Pharmaceuticals in its sale to Endo Pharmaceuticals.*

 *matter handled prior to joining Honigman LLP

Prior Experience

• Prior to joining Honigman, Mr. Rosenberg practiced at a number of international law firms.

Additional Languages

• Hebrew, conversational – near fluent

Education

Admissions

Press Releases